NKNoboru Kubodera

Noboru Kubodera

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Noboru Kubodera has a total of 28 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

    • 1 January 2012
      • Vol. 32  (1) , 303-9

    Process development for the practical production of eldecalcitol by linear, convergent and biomimetic syntheses.

    by Noboru Kubodera, Susumi Hatakeyama

    Eldecalcitol [1α,25-dihydroxy-2β-(3-hydroxypropoxy)vitamin D(3)], an analog of calcitriol (1α,25-dihydroxyvitamin D(3)), possesses a hydroxypropoxy substituent at the 2β-position of calcitriol. Eldecalcitol has potent biological effects on bone disease such as osteoporosis. The marketing of eldecalcitol has very recently started in Japan. In consideration of this, we have been investigating practical synthesis of eldecalcitol for industrial-scale production. Eldecalcitol was initially synthesized in a linear manner. The 27-step linear sequence was, however, suboptimal due to its lengthiness and low overall yield (ca. 0.03%). Next, we developed a convergent approach based on the Trost coupling reaction, in which the A-ring fragment (ene-yne part obtained in 10.4% overall yield) and the C/D-ring fragment (bromomethylene part obtained in 27.1% overall yield) are coupled to produce the triene system of eldecalcitol (15.6%). Although the overall yield of the convergent synthesis was better than that of the linear synthesis, significant improvements were still necessary. Therefore, additional biomimetic studies were investigated. Process development for the practical production of eldecalcitol is described herein.

  • D-Hormone Derivatives for the Treatment of Osteoporosis: From Alfacalcidol to Eldecalcitol

    by Noboru Kubodera

    Many readers may have only a vague idea about vitamin D. This is made complicated, in part, because it is also expressed with suffixes such as vitamin D2 or vitamin D3. Otherwise the prefix of “active” is also occasionally used. Vitamin D is often referred to as an important nutrient for calcium intake, especially for growing children and the elderly. On the other hand, it serves as a therapeutic drug for osteoporosis and psoriasis. Recent studies have suggested an association with a number of diseases such as cancer, diabetes and Alzheimers disease. The author has been involved in the research and development of vitamin D applications for over 25 years, and has often witnessed even world-class experts confuse the two roles - vitamin and hormone - of “substance” D. Assuming some readers are not familiar with vitamin D, D hormone or osteoporosis, an outline of vitamin D and D hormone is delineated with a particular focus on the treatment of osteoporosis. Furthermore, development of alfacalcidol as the first prodrug of D hormone (calcitriol) and eldecalcitol as a characteristic new D hormone derivative and basic relationship between calcemic activity and effect on bone in vitamin D (cholecalciferol), D hormone (calcitriol/alfacalcidol), and a new D hormone derivative (eldecalcitol) are introduced.


  • Open Access

    A New Look at the Most Successful Prodrugs for Active Vitamin D (D Hormone): Alfacalcidol and Doxercalciferol

    by Noboru Kubodera

    Alfacalcidol (1α-hydroxyvitamin D3) has been widely used since 1981 as a prodrug for calcitriol (1α,25-dihydroxyvitamin D3) in the treatment of hypocalcemia, chronic renal failure, hypoparathyroidism and osteoporosis. More recently, doxercalciferol (1α-hydroxyvitamin D2) has been used since 1999 as a prodrug for 1α,25-dihydroxyvitamin D2 for the treatment of secondary hyperparathyroidism. Currently, six forms of vitamin D are known. They range from vitamin D2 to vitamin D7 and are distinguished by their differing side chains. Only vitamin D2 and vitamin D3 have been found to be biologically active based on the elucidation of activation pathways. Alfacalcidol and osteoporosis/doxercalciferol and secondary hyperparathyroidism are discussed, with a new look at old compounds including their practical syntheses.


    • 1 September 2009
      • Vol. 29  (9) , 3571-8

    Synthesis of all possible A-ring diastereomers at the 1- and 3-positions of 1alpha,25-dihydroxy-2beta-(3-hydroxypropoxy)vitamin D3 (ED-71) using C2-symmetrical epoxide as a common starting material.

    by Noboru Kubodera, Susumi Hatakeyama

    The active vitamin D3, 1alpha,25-dihydroxyvitamin D3 (1,25(OH)2D3), is now well recognized as a potent regulator of cell proliferation and differentiation in addition to possessing a regulatory effect on calcium and phosphorus metabolism. From research on the synthesis of 1,25(OH)2D3 analogs with the goal of separating these biological activities, we have already reported two characteristic analogs of active vitamin D3, namely 1alpha,25-dihydroxy-22-oxavitamin D3 (OCT) and 1alpha,25-dihydroxy-2beta-(3-hydroxypropoxy) vitamin D3 (ED-71). OCT, a 22-oxa analog obtained from modification of the side chain of 1,25(OH)2D3, has been used clinically as an injection for the treatment of secondary hyperparathyroidism underlying renal insufficiency and as an ointment for the skin disease, psoriasis. OCT has also been reported to exhibit antiangiogenic activity, exerting antitumor effects without producing serious side effects such as hypercalcemia. On the other hand, ED-71, which possesses a hydroxypropoxy substituent at the 2beta-position of the A-ring of 1,25(OH)2D3, has more potent biological effects on bone compared to 1 and phase III clinical studies for bone-fracture prevention have been completed. To explore structure activity relationship between ED-71 and related analogs, significant attention was now focused on the diastereomer of 3 at both the 1- and 3-positions of the A-ring, namely 3-epi-ED-71, 1-epi-ED-71 and 1,3-diepi-ED-71. All possible A-ring diastereomers at the 1- and 3-positions of ED-71 were synthesized using C2-symmetrical epoxide as a common starting material by convergent Trost methodology.

  • A new active vitamin D analog, ED‐71, causes increase in bone mass with preferential effects on bone in osteoporotic patients

    by N. Kubodera, N. Tsuji, Y. Uchiyama, K. Endo

    As a candidate for active vitamin D analogs that have selective effects on bone, 1α,25‐dihydroxy‐2β‐(3‐hydroxypropoxy)vitamin D3 (ED‐71) has been synthesized and is currently under clinical trials. In ovariectomized rat model for osteoporosis, ED‐71 caused an increase bone mass at the lumbar vertebra to a greater extent than 1α‐hydroxyvitamin D3 (alfacalcidol), while enhancing calcium absorption and decreasing serum parathyroid hormone levels to the same degree as alfacalcidol. ED‐71 lowered the biochemical and histological parameters of bone resorption more potently than alfacalcidol, while maintaining bone formation markers.An early phase II clinical trial was conducted with 109 primary osteoporotic patients. The results indicate that oral daily administration of ED‐71 (0.25, 0.5, 0.75, and 1.0 μg) for 6 months increased lumbar bone mineral density in a dose‐dependent manner without causing hypercalcemia and hypercalciuria. ED‐71 also exhibited a dose‐dependent suppression of urinary deoxypyridinoline with no significant reduction in serum osteocalcin. These results demonstrate that ED‐71 has preferential effects on bone with diminished effects on intestinal calcium absorption. ED‐71 offers potentially a new modality of therapy for osteoporosis with selective effects on bone. J. Cell. Biochem. 88: 286–289, 2003.


    • 1 March 2002
      • p. 517-28

    [Drugs in development for the treatment of osteoporosis: Active vitamin D analog(ED-71)].

    by Noboru Kubodera, Naoki Tsuji, Yasushi Uchiyama

  • Asymmetric catalytic ene‐cyclization approach to 2–fluoro‐19‐nor‐1,25‐dihydroxyvitamin D3 A‐ring analog with significant transactivation activity

    by Koichi Mikami, Shiho Ohba, Hirofumi Ohmura, Noboru Kubodera, Kimie Nakagawa, Toshio Okano

    1α,25-Dihydroxyvitamin D3 (1α,25(OH)2D3) has been shown to modulate not only proliferation and differentiation, but also apoptosis in malignant cells, indicating that it could be useful for the treatment of cancer and psoriasis. However, little information has been available on the binding conformation of the 1α,25(OH)2D3 molecule and its analogs with the vitamin D receptor (VDR). Therefore, we synthesized 2α-fluorinated A-ring analogs of 19-nor-1α,25(OH)2D3 in order to investigate the VDR-binding conformation of the A-rings on the basis of the 19F NMR analysis. The 2α–fluoro-19-nor-1α,25-dihydroxyvitamin D3 A-ring analog thus synthesized via a asymmetric catalytic carbonyl-ene cyclization, shows significant activity in transactivation. Chirality 13:366–371, 2001.


  • Syntheses and preventive effects of analogues related to 1α,25-dihydroxy-2β-(3-hydroxypropoxy)vitamin D3 (ED-71) on bone mineral loss in ovariectomized rats

    by Yoshiyuki Ono, Akira Kawase, Hiroyoshi Watanabe, Ayako Shiraishi, Satoshi Takeda, Yoshinobu Higuchi, Katsuhiko Sato, Tsuyoshi Yamauchi, Tetsuhiro Mikami, Masahiro Kato, et al.


  • Practical Formation of γ-Keto or γ-Hydroxy Ether Linkage from Alcohol1

    by Tetsuhiro Mikami, Tomoyasu Iwaoka, Masahiro Kato, Hiroyoshi Watanabe, Noboru Kubodera

    A practically useful formation of γ-keto or γ-hydroxy ether linkage from alcohol, for the construction of the side chain of 1α, 25-dihydroxy-22-oxavitamin D3 (OCT), is described.